Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2024-03-26 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
关于股东部分股份解除质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by a major shareholder of the company. It details the number of shares released from pledge, the shareholder involved, and the impact on control and company operations. There are no financial statements, earnings data, or management discussion. The document is a regulatory announcement about share pledge status, which fits the category of Share Issue/Capital Change (SHA) as it relates to changes in share capital status (release of pledged shares). The document length is short and it is not an announcement of a report publication or certification, so it is not RPA or RNS. Therefore, the best classification is SHA with high confidence.
2024-03-26 Chinese
关于股东部分股份质押到期的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expiration of pledged shares held by a major shareholder of the company. It details the number of shares pledged, the expiration date, and the status of the pledge, along with assurances about the financial status and risk related to the pledge. There are no financial statements, management discussion, or detailed financial data. The document is a regulatory announcement about shareholder share pledge status, which fits the category of a Regulatory Filing (RNS) as it is a compliance disclosure related to share pledges and does not fit into more specific categories like capital changes or director dealings.
2024-03-20 Chinese
关于子公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Dongbei Pharmaceutical Group Co., Ltd. regarding its subsidiary receiving a drug registration certificate from the National Medical Products Administration. It details the drug's registration information, approval, and potential impact on the company. The document is short (1369 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, or meeting materials. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories like Annual Report, Earnings Release, or Capital Update.
2024-02-05 Chinese
关于公司原料药左卡尼汀收到欧洲药品质量管理局签发CEP证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a CEP certificate from the European Directorate for the Quality of Medicines (EDQM) for a raw material drug (Levocarnitine). It describes the certificate details, product information, and the impact on the company. The document is short (799 characters) and serves as an official announcement of a regulatory or certification event rather than a financial report or detailed filing. There is no financial data, no mention of shareholder votes, no management changes, no earnings or capital updates, and no legal proceedings. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2024-01-28 Chinese
关于公司2023年度日常关联交易执行情况及2024年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Dongbei Pharmaceutical Group Co., Ltd. regarding the execution of daily related party transactions for the year 2023 and the forecast for 2024. It includes transaction amounts, pricing principles, related parties' information, and approvals by the board and independent directors. The content focuses on disclosure of related party transactions, their compliance with regulations, and board approvals. It is not a full financial report, audit report, or earnings release, but a regulatory announcement about related party transactions. This type of document fits best under Regulatory Filings (RNS) as it is a compliance disclosure and does not contain comprehensive financial statements or detailed financial analysis typical of Annual or Interim Reports.
2024-01-18 Chinese
第九届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 24th meeting of the 9th Board of Directors of Dongbei Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results, and references a related announcement about related party transactions. The document does not contain financial statements or detailed financial data but rather reports on board decisions and meeting procedures. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management.
2024-01-18 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.